HK1257679A1 - 使用l-鸟苷酸与苯乙酸根和苯基丁酸根中至少一种的结合治疗和预防神经元细胞损失 - Google Patents

使用l-鸟苷酸与苯乙酸根和苯基丁酸根中至少一种的结合治疗和预防神经元细胞损失 Download PDF

Info

Publication number
HK1257679A1
HK1257679A1 HK19100043.6A HK19100043A HK1257679A1 HK 1257679 A1 HK1257679 A1 HK 1257679A1 HK 19100043 A HK19100043 A HK 19100043A HK 1257679 A1 HK1257679 A1 HK 1257679A1
Authority
HK
Hong Kong
Prior art keywords
phenylbutyrate
phenylacetate
ornithine
combination
neuronal cell
Prior art date
Application number
HK19100043.6A
Other languages
English (en)
Chinese (zh)
Inventor
Christopher F. ROSE
Marc-André CLÉMENT
Cristina R. BOSOI
Mariana Macedo OLIVEIRA
Mélanie TREMBLAY
Chantal BÉMEUR
Original Assignee
Ocera Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocera Therapeutics, Inc. filed Critical Ocera Therapeutics, Inc.
Publication of HK1257679A1 publication Critical patent/HK1257679A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK19100043.6A 2015-09-25 2016-09-22 使用l-鸟苷酸与苯乙酸根和苯基丁酸根中至少一种的结合治疗和预防神经元细胞损失 HK1257679A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562233002P 2015-09-25 2015-09-25
US201562233002P 2015-09-25
PCT/US2016/053176 WO2017053613A1 (en) 2015-09-25 2016-09-22 Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate

Publications (1)

Publication Number Publication Date
HK1257679A1 true HK1257679A1 (zh) 2019-10-25

Family

ID=58387333

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19100043.6A HK1257679A1 (zh) 2015-09-25 2016-09-22 使用l-鸟苷酸与苯乙酸根和苯基丁酸根中至少一种的结合治疗和预防神经元细胞损失

Country Status (7)

Country Link
US (1) US20200206174A1 (enExample)
EP (1) EP3352748A4 (enExample)
JP (1) JP6989495B2 (enExample)
AU (1) AU2016325556B2 (enExample)
CA (1) CA2998490A1 (enExample)
HK (1) HK1257679A1 (enExample)
WO (1) WO2017053613A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810464B (zh) 2009-04-03 2019-01-22 欧塞拉治疗有限公司 L-鸟氨酸苯乙酸盐及其制备方法
ES2517340T3 (es) 2009-06-08 2014-11-03 Ucl Business Plc Tratamiento de la hipertensión portal usando L-ornitina y fenilacetato
KR20230018526A (ko) 2014-11-24 2023-02-07 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
WO2017083758A1 (en) * 2015-11-13 2017-05-18 Ocera Therapeutics, Inc. Formulation of l-ornithine phenylacetate
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
WO2019036471A1 (en) 2017-08-14 2019-02-21 Axcella Health Inc. AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE
US20210186937A1 (en) * 2018-05-22 2021-06-24 Duke University Compositions and methods for treating neurodegenerative disorders with rifaximin
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
CA3138914A1 (en) * 2019-05-09 2020-11-12 Ocera Therapeutics, Inc. Methods of assessing and treating hepatic encephalopathy
US12697317B2 (en) 2019-10-16 2026-08-04 Amalive Limited Dosages and uses of ornithine phenylacetate for treating hyperammonemia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
CN1304723A (zh) * 2001-01-16 2001-07-25 中山大学 含二氢呋喃环结构的丹参酮类化合物用于治疗肝性脑病的药物
PT2319581E (pt) * 2004-11-26 2015-06-30 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
CN106810464B (zh) 2009-04-03 2019-01-22 欧塞拉治疗有限公司 L-鸟氨酸苯乙酸盐及其制备方法
ES2517340T3 (es) * 2009-06-08 2014-11-03 Ucl Business Plc Tratamiento de la hipertensión portal usando L-ornitina y fenilacetato

Also Published As

Publication number Publication date
CA2998490A1 (en) 2017-03-30
US20200206174A1 (en) 2020-07-02
JP6989495B2 (ja) 2022-01-05
EP3352748A4 (en) 2019-06-05
WO2017053613A1 (en) 2017-03-30
EP3352748A1 (en) 2018-08-01
WO2017053613A8 (en) 2017-04-27
AU2016325556B2 (en) 2023-02-16
AU2016325556A1 (en) 2018-03-01
JP2018531929A (ja) 2018-11-01

Similar Documents

Publication Publication Date Title
WO2017053613A8 (en) Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
AU2015214400B2 (en) Self-priming systems and methods
HK1249434A1 (zh) 使用与苯乙酸盐和苯丁酸盐中的至少一种组合的l-鸟氨酸治疗和预防肌肉损失
MX2018002320A (es) Abrazaderas quirurgicas de diseccion.
HK1251624A1 (zh) Kras表达的调节剂
TN2016000553A1 (en) Methods and compositions for treating ulcers
WO2014015274A8 (en) Methods for tissue passivation
WO2016037138A8 (en) Globin gene therapy for treating hemoglobinopathies
HK1246151A1 (zh) 为t细胞疗法而调理患者的方法
WO2018009512A8 (en) Solids handling in water treatment systems and associated methods
SG10201901010PA (en) Combination therapy for treating a paramyxovirus
EP3520395A4 (en) OPTICAL SYSTEMS FOR SURGICAL PROBES, SYSTEMS AND METHODS THEREFOR AND METHOD FOR CARRYING OUT SURGICAL INTERVENTIONS
EP3331459A4 (en) DEVICES, SYSTEMS, AND METHODS OF COLLECTION FOR USE IN BONE TISSUE
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
EA201270803A1 (ru) Тиоацетатные соединения, композиции на их основе и способы их применения
EP3434170A4 (en) ENDOSCOPE DEVICE, ENDOSCOPE SYSTEM, AND SURGICAL SYSTEM THEREFOR
WO2017106364A3 (en) Compositions and methods for treatment of retinitis pigmentosa 18 and retinitis pigmentosa 13
MY194227A (en) Modulators of pcsk9 expression
EA202190708A1 (ru) Модуляторы экспрессии pnpla3
EP3370633A4 (en) ORTHOPEDIC FASTENER, HOLDER AND GUIDANCE
EP3745967A4 (en) DEVICES AND METHODS FOR TREATMENT OF BLOCKED BLOOD VESSELS
MX2025006207A (es) Composiciones que contienen arginasa i humana con un cofactor de metal de cobalto para usarse en el tratamiento de la deficiencia de arginasa 1
WO2012158672A3 (en) Compounds for use in treatment of mucositis
HK1258276A1 (zh) 用於治疗hiv的化合物和组合
GB201504607D0 (en) Methods,tools and systems for the assessment,preventation,management and treatment selection for type 2 diabetes